Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» dry eye disease
dry eye disease
Bausch + Lomb Buys J&J’s Dry Eye Drops for $106.5M in Expansion of OTC Business
Bausch + Lomb Buys J&J’s Dry Eye Drops for $106.5M in Expansion of OTC Business
BioSpace
Bausch + Lomb
dry eye disease
OTC
JNJ Vision
Flag link:
Bausch + Lomb to acquire Xiidra, ‘front of eye’ assets from Novartis
Bausch + Lomb to acquire Xiidra, ‘front of eye’ assets from Novartis
Healio
Bausch + Lomb
M&A
Novartis
Xiidra
dry eye disease
Flag link:
FDA Approves Bausch + Lomb, Novaliq Dry Eye Disease Drug
FDA Approves Bausch + Lomb, Novaliq Dry Eye Disease Drug
BioSpace
Bausch + Lomb
Novaliq
Miebo
FDA
dry eye disease
Flag link:
Aldeyra reports positive data from dry eye disease therapy trial
Aldeyra reports positive data from dry eye disease therapy trial
Clinical Trials Arena
Aldeyra Therapeutics
clinical trials
reproxalap
dry eye disease
Flag link:
Aldeyra’s sights set on November PDUFA
Aldeyra’s sights set on November PDUFA
Endpoints
Aldeyra Therapeutics
dry eye disease
reproxalap
FDA
Flag link:
Aurinia Pharma, Sun Pharma enter into settlement agreement for dry eye disease drug
Aurinia Pharma, Sun Pharma enter into settlement agreement for dry eye disease drug
Medical Dialogues
Aurinia Pharmaceuticals
Sun Pharma
dry eye disease
Cequa
Flag link:
Iveric hits again in pivotal eye disease program, keeping it on Apellis' tail in race to market
Iveric hits again in pivotal eye disease program, keeping it on Apellis' tail in race to market
Fierce Biotech
Iveric Bio
Apellis Pharmaceuticals
clinical trials
FDA
dry eye disease
geographic atrophy
Flag link:
Oyster Point plows ahead with 50 layoffs to focus on approved eye drug
Oyster Point plows ahead with 50 layoffs to focus on approved eye drug
Fierce Biotech
Oyster Point Pharma
layoffs
dry eye disease
Flag link:
Aldeyra says eye drop clears three dry eye signals en route to FDA
Aldeyra says eye drop clears three dry eye signals en route to FDA
Endpoints
Aldeyra Therapeutics
dry eye disease
FDA
clinical trials
reproxalap
Flag link:
Oyster Point Laying Off 50 with Focus on Dry Eye Drug Launch
Oyster Point Laying Off 50 with Focus on Dry Eye Drug Launch
BioSpace
Oyster Point Pharma
layoffs
dry eye disease
Tyrvaya
Flag link:
Aldeyra Prepares to Submit Dry Eye Disease Treatment Reproxalap to FDA
Aldeyra Prepares to Submit Dry Eye Disease Treatment Reproxalap to FDA
BioSpace
Aldeyra Therapeutics
dry eye disease
reproxalap
clinical trials
Flag link:
With lung drug from Pfizer in hand, AN2 tests IPO waters in turbulent market
With lung drug from Pfizer in hand, AN2 tests IPO waters in turbulent market
MedCity News
AN2 Therapeutics
Okyo Pharma
IPOs
clinical trials
lung disease
dry eye disease
Flag link:
Aldeyra builds case for troubled dry eye drug reproxalap
Aldeyra builds case for troubled dry eye drug reproxalap
Pharmaforum
Aldeyra Therapeutics
dry eye disease
reproxalap
Flag link:
Why Pfizer Isn't the Big Winner With a Newly Approved Version of Chantix
Why Pfizer Isn't the Big Winner With a Newly Approved Version of Chantix
Motley Fool
Pfizer
Chantix
dry eye disease
Oyster Point Pharma
Flag link:
FDA OKs an inhaled version of smoking cessation drug Chantix — for a common eye disease
FDA OKs an inhaled version of smoking cessation drug Chantix — for a common eye disease
Endpoints
Oyster Point Pharma
Tyrvaya
FDA
dry eye disease
Chantix
Flag link:
Aerie CEO exits days after downplaying midphase eye disease flop
Aerie CEO exits days after downplaying midphase eye disease flop
Fierce Biotech
Aerie CEO
Vicente Anido
TRPM8
dry eye disease
Flag link:
Aerie touts silver linings from failed PhIIb, plots PhIII in dry eye disease
Aerie touts silver linings from failed PhIIb, plots PhIII in dry eye disease
Endpoints
Aerie Pharmaceuticals
clinical trials
dry eye disease
AR-15512
Flag link:
Oyster Point Pharma Inks Deal with Ji Xing for Dry Eye Disease Therapies
Oyster Point Pharma Inks Deal with Ji Xing for Dry Eye Disease Therapies
BioSpace
Oyster Point Pharma
Ji Xing Pharmaceuticals
OC-01
OC-02
dry eye disease
China
Flag link:
AbbVie revives DTC ads for dry eye med Restasis with a patient front and center
AbbVie revives DTC ads for dry eye med Restasis with a patient front and center
Fierce Pharma
Allergan
Restasis
dry eye disease
DTC advertising
television ads
Flag link:
Two biotechs target dry eye disease after Novartis’ Xiidra problems
Two biotechs target dry eye disease after Novartis’ Xiidra problems
Pharmaforum
dry eye disease
Novartis
Xiidra
Sylentis
Azura Ophthalmics
Flag link:
Pages
1
2
3
4
5
next ›
last »